Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
Phase 1
Completed
- Conditions
- MetastasisLocally Advanced Solid TumorRecurrent Cancer
- Interventions
- Radiation: Palliative radiotherapy
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- XRad Therapeutics Inc
- Target Recruit Count
- 12
- Registration Number
- NCT05002140
- Locations
- 🇺🇸
Stanford Clinical Cancer Center, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
News
No news found